COMPANY PROFILE

Hallux

An innovative clinical stage pharmaceutical company focused on developing safe and highly effective breakthrough solutions for common infections of the toe, nail and foot

Laguna Hills, United StatesFounded 2012Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Hallux

Hallux Inc. is a biotechnology company focused on developing innovative treatments for onychomycosis, a fungal infection affecting the toenails. The company operates in the healthcare and pharmaceutical market, primarily targeting the 35 million Americans suffering from this condition. Hallux's core product is a subungual topical treatment designed to be both safe and highly effective, addressing the limitations of current prescription products that are only marginally successful. The business model revolves around conducting clinical trials to validate the efficacy, safety, and tolerability of their treatment, with the goal of obtaining regulatory approval and commercializing the product. Revenue is generated through the sale of their proprietary treatment once it reaches the market. Hallux serves patients with moderate to severe distal lateral subungual onychomycosis, offering a promising solution to a widespread and persistent problem.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Laguna Hills, United States
Employees: 6
Open positions: None listed
Dealroom signal: 26.3/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Apr 2022	$9.4M	$38M	Undisclosed	↗
DEBTDebt	Nov 2018	$2.2M	—	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Hallux website traffic

Latest recorded traffic for Hallux is 600 monthly website visits, down 32.6% over the last three months. Hallux's team grew 0% over the past year.

Latest monthly visits600 3-month web change-32.6% 1-year team growth0%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AFAlpha FusionFusion of leading-edge scientists teaming in Nuclear Physics, Organic Chemistry, and Nuclear Medicine	Osaka, Japan	Operational	—	$12M	$31M
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
TRtranScripSpecialist pharmaceutical consultancy for the entire product lifecycle	Wokingham, United Kingdom	Acquired
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational